To describe successful endoluminal revascularization of an acute M1 occlusion 4 days after craniotomy and tumor resection. CLINICAL PRESENTATION: A 16-year-old right-handed girl presented with a 1-month history of daily headaches. The neurological examination was normal. Magnetic resonance imaging and computed tomography demonstrated a mass consistent with an epidermoid tumor compressing the left upper pons, left cerebral peduncle, and mesial left temporal lobe. INTERVENTION: A combination of low-dose antiplatelet agents administered intraarterially and stent-assisted angioplasty was used. Successful endoluminal revascularization was achieved. Acute complications such as intracranial stent-thrombosis and/or intracranial hemorrhage were successfully avoided. CONCLUSION: In the acute postoperative period, most current chemical thrombolytic protocols are contraindicated because of the prohibitive risk of iatrogenic intracranial hemorrhage. With an understanding of the pharmacokinetics of the currently available antiplatelet drugs, combined chemical and mechanical thrombolysis may be used in the acute postoperative setting for endoluminal recanalization. www.neurosurgery-online.com P erioperative cerebral thromboembolic events are difficult to manage because of the risks of intracranial hemorrhage (ICH) when thrombolytic agents such as fibrinolytics (e.g., tissue plasminogen activator [t-PA], urokinase) and platelet inhibitors (IIb/IIIa inhibitors) are introduced into the systemic circulation, thus interacting with the surgical bed. Nevertheless, when faced with a potentially reversible situation, it is difficult to abandon an ischemic episode that is likely to lead to severe disability or death if left untreated. The judicious use of thrombolytics along with mechanical revascularization techniques may allow surgeons to more safely treat perioperative thromboembolic disease that has been considered contraindicated until now.
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CASE REPORT
A 16-year-old right-handed girl presented with a 1-month history of daily severe headaches. The patient had no family history of migraines and used no prescribed or illicit medications. The neurological examination was normal. Magnetic resonance imaging and computed tomographic (CT) scans demonstrated a mass consistent with an epidermoid tumor compressing the left upper pons, left cerebral peduncle, and mesial left temporal lobe (Fig. 1) .
Surgical resection of the lesion was carried out via a left anterolateral craniotomy with orbital osteotomy and intraoperative neuronavigation. To access the temporal component of the tumor as well as the portion compressing the brainstem, the sylvian fissure was opened along the left middle cerebral artery (MCA) back to the MCA bifurcation, and a small portion of the left uncus was resected. A portion of the lesion that was adherent to the peduncle and thalamus as well as a portion deep within the temporal lobe was intentionally left behind. All tumor compressing the pons and peduncle was removed.
The patient awoke from surgery with a normal neurological examination in terms of strength and speech. Approximately 1 hour later, however, she developed right-sided hemiparesis, confusion, and dysarthria/ dysphasia. Despite having been loaded with phenytoin during surgery, an electroencephalogram revealed delta Grade II focal left frontal activity with projected type Grade III dysrhythmia and focal left frontal and left temporal sharp waves. Additional anticonvulsant medication was administered, and within 2 hours, the patient returned to normal. Magnetic resonance imaging revealed some ischemic changes in the caudate and corona radiata (Fig. 2) .
Four days later, the patient again developed right-sided hemiparesis, which progressed to hemiplegia along with receptive aphasia (National Institutes of Health score of 17). A CT scan showed new hypodensities within the left basal ganglia representing the expected evolution of the infarctions previously revealed on magnetic resonance imaging (Fig. 3) . Phenytoin levels were therapeutic. An emergent arteriogram was ordered to evaluate the patient for a vascular abnormality.
A left common carotid arteriogram revealed no carotid dissection or other vascular irregularity. A left internal carotid arteriogram, however, demonstrated a left MCA bifurcation occlusion with only moderate reconstitution of the distal MCA territory from anterior circulation collaterals (Fig. 4) . Because the patient had undergone a craniotomy 4 days earlier with accompanying uncal resection, we were loathe to administer superselective thrombolytic agents intra-arterially for fear of inducing an intracranial hematoma in the patient's dominant hemisphere. Mechanical revascularization was therefore selected.
After a 6-French Envoy guiding catheter (Cordis Endovascular, Miami Lakes, FL) was advanced into the left internal carotid artery, a RapidTransit 0.018-in microcatheter (Cordis Endovascular) was advanced over a Gold Tip 0.018-in wire (Terumo/ Boston Scientific, Natick, MA) across the MCA occlusion and into the M3 segment. The microcatheter was removed, and a 2-mm by 10-mm D1 coronary angioplasty balloon (Medtronic, Galway, Ireland) was advanced across the MCA bifurcation into the superior division. Multiple balloon inflations were carried out; however, the vessel continued to open and then reocclude (Figs. 5 and 6 ). Despite 3 mg of the IIb/IIIa inhibitor eptifibatide (Integrilin) (Key Pharmaceuticals, Kenilworth, NJ) being infused into the MCA, the artery would not remain recanalized. At this point, a 2-mm by 10-mm Abbott BiodivYsio coated stent (Abbott Laboratories, Redwood City, CA) was advanced across the MCA bifurcation and inflated to 8 atm for a final diameter of 2.08 mm. A repeat angiographic image showed patency of the MCA and its major divisions (Fig. 7) . The patient was given 3 mg of Integrilin intravenously, and a repeat angiographic image 10 minutes later showed continued patency. The patient was then given 300 mg of clopidogrel (Plavix; Bristol-Myers Squibb/Sanofi Pharmaceuticals, New York, NY) orally and transferred to the CT scanner for a CT perfusion study, which showed no defect or asymmetry in the volume, flow, or transit time.
The patient regained all function during the ensuing 24 to 48 hours and was discharged with subtle neurological deficit (National Institutes of Health score of 1; upper-extremity drift before 10 s). Follow-up CT scans demonstrated no new infarction. Subsequent workup for an embolic source was negative. Lower-extremity venous Doppler ultrasonography, transesophageal echocardiography with a bubble study, and pulmonary CT scanning failed to disclose a deep venous thrombosis, right-to-left shunt, or arteriovenous fistula.
DISCUSSION
We have recently detected a growing interest in novel interventional therapies for acute stroke. Although intravenous infusion of t-PA for acute thromboembolic stroke was approved in 1996 by the United States Food and Drug Administration on the basis of the positive results of the National Institute of Neurological Disorders and Stroke (NINDS) study (9) , such intervention is only applicable for patients presenting within 3 hours of stroke onset. This limitation significantly reduces the number of patients that may benefit from thrombolysis. As a result, newer intra-arterial therapies are currently under investigation.
Two early trials evaluating the efficacy of intra-arterial therapy have paved the way for further studies. These randomized, multicenter, placebo-controlled trials were the Prolyse in Acute Cerebral Thromboembolism (PROACT) I and II trials (3, 4) . Patients with acute ischemic stroke with onset of symptoms within 6 hours underwent intra-arterial thrombolysis with recombinant pro-urokinase (r-pro UK). Recanalization results and rates were based on the Thrombolysis in Myocardial Infarction (TIMI) grading system. In PROACT I, TIMI 2 or 3 rates were 58% in the r-pro UK group and 14% in the placebo group. The clinical efficacy of this treatment modality could not be established because of the trial's limited power; thus, a larger study, PROACT II, was performed. This trial was designed to assess the efficacy of r-pro UK administered arterially (9 mg administered during 2 h as opposed to 6 mg in PROACT I), as measured by a modified Rankin Scale score of 2 or less at 90 days. Forty percent of r-pro UK patients and 25% of control patients achieved a modified Rankin Scale score of 2 or less at 90 days (P ϭ 0.04). Recanalization rates (TIMI 2 or 3) were 66% in the r-pro UK group and 18% in the placebo group in the PROACT II trial. The study showed a 15% absolute increase in favorable outcome with r-pro UK.
Combined intra-arterial and intravenous therapies have revealed promise for patients with acute stroke. On the basis of the findings of the Emergency Management of Stroke bridging trial (8, 11) , the NINDS has funded a Phase II pilot study, the Interventional Management of Stroke trial (2) . This study is designed to assess the safety and efficacy of t-PA administered by a combined intravenous/intra-arterial route within 3 hours of symptom onset in patients with a National Institute of Health Stroke Scale score of 10 or greater. Patients received 0.6 mg/kg of t-PA administered intravenously during 30 minutes (15% as a bolus) and then t-PA (up to 22 mg) administered intra-arterially during 2 hours. Preliminary analysis of the study showed 16% mortality at 3 months in the t-PA group (compared with 24% in the NINDS placebo group) and a 6% rate of symptomatic ICH (compared with 1% in the NINDS placebo group). TIMI 2 and 3 recanalization rates were 40% in the t-PA group versus 10% in the placebo group.
Although chemical thrombolysis is effective some patients, including those whose symptoms extend beyond 6 hours from presentation or who have had recent surgery, others are excluded from receiving therapy because of an increased risk of ICH and systemic hemorrhage. For these patients, mechanical thrombolysis has emerged as a viable alternate therapy. The goals of mechanical thrombolysis are to achieve arterial recanalization while minimizing the chances of intracerebral hemorrhage. Despite a number of devices being currently tested, no mechanical devices are currently approved by the United States Food and Drug Administration.
The case presented here is unique in that the patient was having intermittent symptoms of hemiparesis and aphasia. Once the MCA occlusion was recognized, we were faced with a patient who was recovering from a craniotomy and tumor resection that was 4 days old, thus precluding her from safely receiving standard intra-arterial lytic therapy. The only alter- native for endoluminal revascularization was mechanical, especially because an underlying focal stenosis was suspected. Several mechanical options currently exist for endoluminal revascularization. These include snares, balloons, stents, and other clot disruption devices such as the ultrasound infusion microcatheter (Ekos Corp., Bothell, WA) and AngioJet (Possis Medical, Minneapolis, MN) (10). All these devices are unproven, and many are limited to use in those individuals enrolled in specified industry-sponsored trials. We elected to use balloon angioplasty alone as our first means of mechanically opening the vessel. A 2-mm by 10-mm D1 coronary balloon was inflated using slow inflation techniques multiple times in the M1 segment of the left MCA. This achieved intermittent recanalization only to be followed by reocclusion. Integrilin was administered intra-arterially at 30% (3 mg) of the 9-mg bolus dose (180 g/kg). Although intravenous administration of IIb/IIIa inhibitors has shown promise in the treatment of acute stroke, intra-arterial administration of IIb/ IIIa has not been widely reported, and there is limited experience in the setting of acute stroke intervention (1, 6) . Intraarterial administration of the agent was performed in an attempt to limit the dose normally used when administering the drug systemically. By local intra-arterial delivery of this agent or other platelet inhibitors into dynamically forming thrombus, we postulate that a maximal effect can be achieved despite a limited dose (5) . After the administration of the Integrilin, a 2-mm by 10-mm stent was delivered across the area of persistent thrombosis and deployed. Given the transient improvement in TIMI flow after balloon angioplasty alone, stent deployment was carried out to achieve a permanent buttress against the reforming thrombus attributed to an underlying stenosis (refractory to balloon angioplasty) in the MCA. In the past, we have used stenting in the setting of acute thromboembolic stroke as a "last resort" and have achieved recanalization (7) . Immediate angiography demonstrated patency of the M1 segment and the distal MCA branches. Given the thrombogenicity of coronary stents, 50% of the remaining Integrilin bolus dose (3 mg of the remaining 6 mg needed to reach a 9-mg bolus dose) was administered intravenously and the patient was loaded with 300 mg of clopidogrel, which would become therapeutic 4 to 6 hours after administration of the drug, coinciding with the time of decreased effectiveness of the Integrilin bolus. By using the antiplatelet regimen described in this case, we were able to avoid our two most feared complications, ICH and/or acute stent thrombosis.
CONCLUSION
We postulate that manipulation of the tumor during resection irritated the left MCA, thus inducing vasospasm and sluggish flow within the left MCA, or that iatrogenic injury to the MCA resulted in a focal stenosis. It is unlikely that the patient had the MCA occlusion at the conclusion of surgery, because the somatosensory evoked potentials and electroencephalography remained normal throughout the operation and her initial examination after surgery was normal. Spasm The patient's lesion was most likely a result of an intimal injury received intraoperatively, because it did not respond to angioplasty as spasm would and was a nidus for continual thrombus formation. The magnetic resonance imaging findings of basal ganglia ischemia consistent with M1 perforator infarction, most likely not explained by direct coagulation of vessels, should have warranted obtaining a computed tomographic angiogram or conventional cerebral angiogram in the earlier postoperative period. One must assume that this patient developed a thrombotic partial occlusion in the immediate postoperative period as the result of an intimal injury that later progressed to complete occlusion. Orally administered antiplatelet medications alone might have helped during that earlier period.
Any degree of anticoagulation in the recent postoperative period must be administered with care and under the realization that a devastating intracranial hemorrhage may result. It is uncommon, but not extremely rare, to treat patients with aspirin, clopidogrel, or even systemic heparinization on Day 4 after craniotomy if it is indicated by other conditions, e.g., intracranial sinus thrombosis, atrial fibrillation, or deep venous thrombosis. It is clear from the literature that combined use of eptifibatide and heparin is associated with an increased rate of hemorrhage compared with simple heparinization (3) . No mention is made of the use of heparinization during the procedure.
It is unclear from the text why the specific dosage of eptifibatide was chosen. A full, intra-arterially or intravenously administered bolus dose of eptifibatide (180 g/kg) for the procedure would not have resulted in greater or less risk of intracranial hemorrhage than the reduced regimen presented in the article. The Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis-II (IMPACT-II) (1) and Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) (2) trials demonstrated that intravenous administration of eptifibatide results in a 250-to 2500-fold molar excess of drug to glycoprotein IIb/IIIa receptor sites, leading to an approximately 80% reduction in platelet aggregation. It is clear, from a pharmacological perspective, that the dose reduction prescribed by the authors (one-third of the bolus dose intra-arterially during angioplasty and another one-third intravenously after stent placement) resulted in little or no alteration in the platelet function compared with the normal intravenous dose because of this stoichiometric relationship. The aforementioned molar excess explains why eptifibatide cannot be reversed with platelets: the new platelets are quickly deactivated by the overwhelming excess of drug relative to receptor sites.
No definitive study at this time delineates the ideal regimen in regard to the intra-arterial treatment of stroke, much less that for intracranial thrombosis status postcraniotomy. In any event, the authors were successful with their combined regimen of angioplasty, stenting, and antiplatelet agent in this single patient. We would, however, caution against use of this case report as a guideline for choosing dosages of intra-arterial eptifibatide, because the platelet effect at that dose is not well known. Of greater importance is the general principle presented here that combined mechanical and pharmacological revascularization is safer and more effective than singlemodality treatment in select patients. L evy et al. describe their experience in a patient who developed MCA occlusion after cranial surgery for an epidermoid tumor. Most likely, the cause of the thrombosis was manipulation during surgery that led to what I believe was a dissection rather than vasospasm. These findings are more consistent with a traumatic injury to the MCA or a traumatic dissection of the MCA from manipulation during tumor resection. In my opinion, the fact that they experienced repeat thrombosis before angioplasty and stenting is more consistent with dissection as a cause rather than vasospasm. The concept of stenting the vessel intracranially because of a dissection is not new.
I think that what at least this one case illustrates is that this can be effective after acute surgical dissection and thrombosis. With the low doses of the thrombolytics used, the authors were able to achieve recanalization, and the patient did not develop an intracranial hemorrhage. Certainly, this type of vascular insult must be considered when a neurological deficit exists and cannot be explained by other causes, as the authors indicated. The authors have achieved a successful management of a very difficult situation.
Robert H. Rosenwasser Philadelphia, Pennsylvania
T he authors report the use of a balloon-expandable stent to treat a perioperative left MCA occlusion refractory to both mechanical (percutaneous angioplasty) and pharmacological thrombolysis. This report demonstrates the appropriate role of intracranial stenting for the management of a presumed thrombotic intracranial occlusion.
Although frequently tempting, refractory thrombus is not by itself an indication for stent placement. If persistent rethrombosis confounds attempts to achieve satisfactory thrombolysis, the addition of a stent would exacerbate this situation, with the stent providing a new and permanent thrombogenic intravascular focus. The only indication for stenting in the setting of stroke thrombolysis is the presence of an underlying lesion that creates a persistent mechanical obstruction resistant to attempted dilation with both compliant and noncompliant angioplasty balloons. The slow or static flow resulting from this type of obstruction creates a hemodynamic environment that promotes rethrombosis.
Given the patient's age and the time course of symptom onset, the most likely cause for a persistent obstruction in the present report is an intraoperative vascular injury sustained during tumor resection. The injured intima not only exposes a thrombogenic endoluminal surface but, in this case, most likely also resulted in a high-grade MCA stenosis, which, in turn, created slow, disordered flow that predisposed the MCA to persistent rethrombosis after percutaneous angioplasty and pharmacological thrombolysis. Although glycoprotein IIb/ IIIa inhibitors address the problem of the exposed thrombogenic subintimal surface and are sometimes sufficient to achieve temporary recanalization, persistent stenosis caused by an underlying lesion (usually an atherosclerotic plaque, but in this case, a vascular dissection injury) often presents durable patency. In such situations, an intracranial stent represents an excellent bailout tool to achieve a luminal diameter that will support a volume of blood flow sufficient to maintain patency after thrombolysis.
The application of a glycoprotein IIb/IIIa inhibitor to achieve and maintain patency after stent placement represents an optimal strategy in the present scenario. These agents provide immediate and effective platelet inhibition, minimizing the formation and propagation of new thrombus formation within the recently deployed stent. They also provide a sufficient time window during which the patient may be converted to oral agents, such as clopidogrel and aspirin. More traditional fibrinolytic agents would be far less favorable in the present perioperative setting, because these agents would function to disrupt stable fibrin cross-linked thrombus at the operative site and predispose the patient to potentially devastating hemorrhagic complications.
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